How expectancy violations facilitate learning to cope with pain – An experimental approach

Background: Expectations of painful sensations constitute a core feature of chronic pain. An important clinical question is whether such expectations are revised when disconfirming experiences are made (e.g., less pain than expected). The present study examined how people adjust their pain expectations when the experience of decreasing pain is expected vs. unexpected. Methods: In a novel experimental paradigm, people who frequently experience pain (N=73) were provided with painful thermal stimulations. Unbeknownst to participants, the temperature applied was decreased from trial to trial. Based on the experimental instructions provided, this experience of decreasing pain was expected in one condition (expectation-confirmation), whereas it was unexpected in another (expectation-disconfirmation). Results: Expectation violations were higher in the expectation-disconfirmation condition than in the expectation-confirmation condition, F(1, 69) = 6.339, p = .014, ηp² = .084. Participants from the expectation-confirmation condition showed a greater adjustment of their pain expectations than the expectation-disconfirmation condition, F(1.666, 114.929) = 7.486, p = .002, ηp² = .098. Across groups, expectation adjustment was related to increases in pain tolerance (r = .342, p = .004) and the ability to cope with pain (r = .234, p = .045) at a one-week follow-up. Conclusions: Participants were more likely to adjust their pain expectations when the experience of decreasing pain was expected. Though participants who experienced large discrepancies between expected and experienced pain were hesitant to adjust their pain expectations immediately, experiencing expectation violations increased their ability to cope with pain one week later, suggesting some beneficial longer-term effects of expectation violations.

A Bayesian Network Concept for Pain Assessment (Preprint)

UNSTRUCTURED Pain is a subjective phenomenon caused/perceived centrally and modified by physical, physiological, or social influences. Currently, the most commonly used approaches for pain measurement rely on self-reporting of pain level on a discrete rating scale. This provides a subjective and only semi-quantitative indicator of pain. This paper presents an approach that combines self-reported pain with pain-related biomarkers to be obtained from biosensors (in development) and possibly other sources of evidence to provide more dependable estimates of experienced pain, a clinical decision support system. We illustrate the approach using a Bayes network, but also describe other artificial intelligence (AI) methods that provide other ways to combine evidence. We also propose an optimization approach for tuning the AI method parameters (opaque to clinicians) so as to best approximate the kinds of outputs most useful to medical practitioners. We present some data from a sample of 379 patients that illustrate several evidence patterns we may expect in real healthcare situations. The majority (79.7%) of our patients show consistent evidence suggesting this biomarker approach may be reasonable. We also found five patterns of inconsistent evidence. These suggest a direction for further exploration. Finally, we sketch out an approach for collecting medical experts’ guidance as to the way the combined evidence might be presented so as to provide the most useful guidance (also needed for any optimization approach). We recognize that one possible outcome may be that all this approach may be able to provide is a quantified measure of the extent to which the evidence is consistent or not, leaving the final decision to the clinicians (where it must reside). Pointers to additional sources of evidence might also be possible in some situations.

Placebo Analgesia Changes on Self-Pain and Empathy for Pain: Influences of Event-Related EEG Oscillations, Heart Rate Variability, and Personality

We induced placebo analgesia (PA), a phenomenon explicitly attenuating the self-pain feeling, to assess whether this resulted in reduced empathy pain when witnessing a confederate undergoing such pain experience. We recorded EEG and electrocardiogram during a painful control and PA treatment in healthy adults who rated their experienced pain and empathy for pain. We derived HRV changes and, using wavelet analysis of non-phase-locked event-related EEG oscillations, EEG spectral power differences for self-pain and other-pain conditions. First-hand PA produced a reduction of self-pain and self-unpleasantness, whereas we observed only a slight decrease of other unpleasantness. We derived linear combinations of HRV and EEG band power changes significantly associated with self-pain and empathy for pain changes using PCAs. We found that relative HR-slowing together with decreased midline ϑ-band (4-8 Hz) power directly influenced self-pain reduction and, indirectly, through chained mediating effects of the Behavioral Inhibition System and Fight-Flight-Freezing System traits. In the other-pain condition, we detected a direct influence of the midline β2-band (22-30 Hz) power reduction on the other-pain decline with a positive mediating role of Total Empathic Ability. These findings suggest that PA modulation of first-hand versus other pain relies on functionally different physiological processes involving different personality traits.

Pain Reduction in Adults with Limb Spasticity Following Treatment with IncobotulinumtoxinA: A Pooled Analysis

Some studies have shown that incobotulinumtoxinA reduces spasticity-associated pain, but further evidence is needed. This exploratory analysis pooled pain-relief data from six Phase 2 or 3 studies of incobotulinumtoxinA (four placebo-controlled studies) for treating upper limb spasticity in adults. Spasticity-associated pain was assessed at baseline and 4 weeks post incobotulinumtoxinA injection using the disability assessment scale (DAS) for pain. Only data for patients with pain at baseline were analysed. Overall, 544 (incobotulinumtoxinA, N = 415; placebo, N = 129) of 937 patients (58.1%) experienced pain at baseline. At Week 4, a significantly greater proportion of incobotulinumtoxinA- (52.1%) than placebo-treated patients (28.7%; Chi-square p < 0.0001) showed a response (≥1-point improvement in DAS pain score). In logistic regression analysis, incobotulinumtoxinA-treated patients were 2.6 times more likely to achieve this endpoint than placebo-treated patients. A significant difference between incobotulinumtoxinA and placebo was observed regardless of baseline pain severity. Additionally, 27.1% of incobotulinumtoxinA- versus 12.4% of placebo-treated patients reported complete pain relief at Week 4 (p = 0.0006). Pain relief increased with multiple injection cycles. To achieve patient-centred care, pain relief may be considered a treatment goal in adults with spasticity-associated pain regardless of pain severity. This study contributes to understanding the benefits of incobotulinumtoxinA in treating limb spasticity-associated pain.

Effects of a Single Application of ScenarTM, a Low-Frequency Modulated Electric Current Therapy, for Pain Relief in Patients with Low Back and Neck Pain: A Randomized Single Blinded Trial

We aimed to demonstrate the antalgic effectiveness of ScenarTM (Self-Controlled Electro Neuro Adaptative Regulation) in patients experiencing low back and neck pain. Sixty patients were included and equally assigned by randomization to a Scenar-On group and to a Scenar-Off group (sham group). All patients received a 20 min application of ScenarTM on the area where they experienced pain. The pain at rest and during movement and the sensation of stiffness were assessed using a numeric rating scale at baseline, immediately after the session and 24 h after the session. The patients’ characteristics at entry were similar between groups. The pain at rest decreased after the session in both groups (from 8 (4) to 5.0 (3) in the Scenar-Off group, p = 0.0001, and from 7 (3) to 4 (4) in the Scenar-On group, p < 0.0001). The difference was not statistically significant for the groups (p = 0.22). Similar results were observed during movement, but the sensation of stiffness was not modified. Such beneficial results did not last until the next day. No undesirable major effects were noticed. Our study does not support the fact that one ScenarTM session improves low back and neck pain better than a sham session.

Effect of Dilution of Propofol on Pain at Site of Injection: Comparison Between 1% vs. 0.33% Formulation

Objective: To study the effect of propofol dilution on pain at injection site with formulations of 1% and 0.33%. Methodology: A randomized controlled trial was conducted for 24 months at the Department of Anaesthesia and Critical Care, Pakistan Institute of Medical Sciences Islamabad. A total of 100 patients were included in the study. Patients were divided into two equal groups: group C received 1% propofol while patients of group D received 0.33% formulation diluted with distilled water. Patients received propofol at the start of anesthesia before any premedication. A 5ml volume was injected over a period of 5s in an 18G cannula over dorsum of hands. Behaviourial pain scale was used and descriptive data analysis was done. Results: Then mean age of patients was 37.36±14.77 with 46 males and 56 females. Pain at the injection site was experienced in 20 (40%) patients of group C whereas 16 (32%) patients experienced pain in group D. There was no association of pain with a strength of propofol solution (p value 0.405). Conclusion: Strength of propofol solution has no association of pain at the injection site and dilution has no better effect in terms of pain score

Site, frequency, and duration of pain in young children with spina bifida

PURPOSE: To investigate the: (1) percent of children with spina bifida (SB) complaining of pain, (2) frequency, duration, and cause of pain by sex, level of lesion type of SB, and ambulation status, (3) body sites reported to hurt, by variables in objective 2, and (4) associations between physical and mental/emotional health between caregiver and child. METHODS: Cross-sectional study of 101 caregivers of children (3 to 6 years old) with SB. Survey data and information from medical records were included. Pearson chi-square, one-way ANOVA, Fisher’s exact test, logistic regressions, and bivariate correlations were used. RESULTS: Seventy percent reported that their child complained of pain, which did not significantly differ by sex, level of lesion, type of SB, or ambulation status. Most (86%) were reported to have experienced pain for less than 24 hours. The most frequently reported pain site was the head, followed by the abdomen and the lower body. Number of pain sites was moderately correlated with frequency of pain complaints. Correlations between how caregivers reported their own physical/mental/emotional health and how they rated that of their children ranged from weak (r = 0.22) to moderate (r = 0.55). CONCLUSION: Almost seven of ten children reportedly complained of pain ranging from at least once a month to everyday. Pain needs to be routinely assessed and treated in this population.

A plain language summary of how well the single-dose Janssen vaccine works and how safe it is

This is a summary of a publication about the ENSEMBLE trial of the Janssen Ad26.COV2.S vaccine against COVID-19, which was published in the New England Journal of Medicine in April 2021. The ENSEMBLE study started in September 2020 and is still ongoing. The study compared the effectiveness of the vaccine to a placebo in 43,783 adults from Latin America, South Africa, and the United States. Of those, 19,630 got a single dose of the vaccine. Compared to the placebo, the vaccine prevented: 66.9% of moderate to severe–critical COVID-19 cases after 14 days 66.1% of moderate to severe–critical COVID-19 cases after 28 days 85.4% of severe COVID-19 cases after 28 days 100% of people with severe COVID-19 from needing to go to hospital for treatment None of the vaccinated participants died from COVID-19. There were 5 people who got the placebo who died from COVID-19. The vaccine was similarly effective in people from all age groups and different countries, including South Africa, where most cases were caused by the beta variant of the virus that originated there. The people in the study who got the vaccine who went on to get COVID-19 generally had milder and fewer symptoms than those who got the placebo. In most people, the vaccine started working after about 2 weeks. After receiving the vaccine, some people experienced pain at the injection site, headache, tiredness, muscle pain, and nausea. In most cases, these were mild and went away within a few days. Serious side effects were very rare. Blood clots, seizures, and tinnitus were very rare but were more common in the people who got the vaccine than in those who got the placebo. At the time of the study, it was not clear if these were caused by the vaccine or not. ClinicalTrials.gov NCT number: NCT04505722 .

Effectiveness of collaboration between oncology pharmacists and anaesthesiologists for inpatient cancer pain management: A pilot study in Taiwan

Objective To evaluate the effectiveness of the collaboration between oncology pharmacists and anaesthesiologists for improving pain control management in cancer patients. Methods This retrospective case–control pilot study enrolled inpatients with active cancer and a pain score of >3 at least once per day for 3 consecutive days. The study group was selected from June 2018 to January 2019. Patients with the same inclusion criteria were selected between November 2017 and May 2018 to serve as the comparison group. The primary outcome was the percentage of patients that experienced pain relief within 7 days from initial pain attack. Results A total of 71 and 77 patients were enrolled in the study and comparison groups. More patients in the study group experienced pain relief within 7 days from the index date (78.9% [56 of 71 patients] versus 72.7% [56 of 77 patients], respectively). The service increased the rate of intervention from attending physicians within 4 days from index date and quality of opioid management. Conclusion The collaboration between oncology pharmacists and anaesthesiologists for cancer pain management may be associated with an increase in the rate of pain relief in cancer patients with poor pain control.

Herpes-zoster-Update – was gibt es Neues?

Shingles are triggered by the reactivation of an infection with the varicella zoster virus (VZV) and are characterized by specific vesicular skin lesions. Mostly, elderly patients are affected. Depending on the affected dermatome, some serious complications can be observed. The introduction of a vaccine against shingles in Germany offers a great potential for reducing the frequency and severity of this disease. There are both a live vaccine, which is no longer recommended, and an inactivated vaccine, which, however, is still not sufficiently recommended to the authorized patient groups and is also only available to a limited extent due to delivery bottlenecks. HZ neuralgia is a serious complication of the disease that requires rapid and effective therapy and should be handed over to experienced pain therapists rather too early than too late. Unfortunately, in everyday clinical practice only a few people are familiar with VZV vasculopathy, which is associated with a significantly increased risk of cerebral insults.